JAZZ

MKT CAP:$12B

Jazz Pharmaceuticals plc

Market Cap

$12B

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Healthcare·Biotechnology·🇮🇪·NASDAQ

Stock Price

$205.62+$32.47 (+18.75%)

Apr 20, 2026

Company Details

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of produc...

CEO

Renee D. Gala

IPO Date

Jun 1, 2007

Website

www.jazzpharma.com

Key Metrics TTM

Revenue

$4.2B

+4.1% YoY

Net Income

-$368M

EPS (Diluted)

-$6.07

Free Cash Flow

$1.3B

Revenue / Share

$67.49

Gross Margin

85.4%

Operating Margin

-11.9%

Net Margin

-8.9%

FCF Margin

32.1%

P/S

2.9x

P/E

—

Earnings Reports

Q4 2025

May 5, 2026

PENDING

FY 2025

Feb 24, 2026

$4.3B+4.9%EPS -$5.84

Q3 2025

Nov 5, 2025

$1.1B+6.7%EPS $4.08

Q2 2025

Aug 6, 2025

$1.0B+2.1%EPS -$11.74

Q1 2025

May 7, 2025

$898M-0.5%EPS -$1.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$897M	$761M	$49M
Q1 22	$814M	$698M	$88M
Q2 22	$933M	$809M	$86M
Q3 22	$941M	$807M	$25M
Q4 22	$972M	$805M	-$263M
Q1 23	$893M	$764M	$126M
Q2 23	$957M	$860M	$158M
Q3 23	$972M	$870M	$172M
Q4 23	$1.0B	$905M	$122M
Q1 24	$902M	$806M	$66M
Q2 24	$1.0B	$914M	$199M
Q3 24	$1.1B	$943M	$260M
Q4 24	$1.1B	$959M	$191M
Q1 25	$898M	$793M	-$56M
Q2 25	$1.0B	$929M	-$686M
Q3 25	$1.1B	$868M	$58M

Valuation

Quarter	P/S	P/E
Q4 21	3.9x	—
Q1 22	3.6x	—
Q2 22	3.5x	—
Q3 22	3.4x	—
Q4 22	3.3x	—
Q1 23	3.2x	—
Q2 23	3.2x	—
Q3 23	3.2x	148.9x
Q4 23	3.1x	29.0x
Q1 24	3.1x	36.3x
Q2 24	3.1x	30.4x
Q3 24	3.0x	26.0x
Q4 24	3.0x	21.5x
Q1 25	3.0x	24.9x
Q2 25	2.9x	—
Q3 25	2.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	$178M	$168M
Q1 22	$209M	$197M
Q2 22	$303M	$291M
Q3 22	$418M	$423M
Q4 22	$342M	$333M
Q1 23	$321M	$317M
Q2 23	$297M	$291M
Q3 23	$307M	$303M
Q4 23	$167M	$139M
Q1 24	$267M	$260M
Q2 24	$331M	$324M
Q3 24	$399M	$388M
Q4 24	$399M	$385M
Q1 25	$430M	$391M
Q2 25	$89M	$101M
Q3 25	$475M	$459M

Capital Expenditures

Quarter	CapEx
Q4 21	$10M
Q1 22	$12M
Q2 22	$12M
Q3 22	$5M
Q4 22	$9M
Q1 23	$4M
Q2 23	$6M
Q3 23	$4M
Q4 23	$28M
Q1 24	$7M
Q2 24	$7M
Q3 24	$11M
Q4 24	$13M
Q1 25	$39M
Q2 25	$12M
Q3 25	$15M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+34.7%	+72.2%
Q1 22	+33.9%	+63.0%
Q2 22	+24.1%	+3.2%
Q3 22	+12.2%	+13.1%
Q4 22	+8.4%	+45.8%
Q1 23	+9.7%	+5.6%
Q2 23	+2.6%	-5.6%
Q3 23	+3.3%	-12.7%
Q4 23	+4.1%	-28.0%
Q1 24	+1.0%	+9.0%
Q2 24	+6.9%	+3.1%
Q3 24	+8.5%	-0.6%
Q4 24	+7.5%	+0.9%
Q1 25	-0.5%	+14.1%
Q2 25	+2.1%	+110.1%
Q3 25	+6.7%	+34.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$53M	5.9%
Q1 22	$50M	6.2%
Q2 22	$54M	5.8%
Q3 22	$57M	6.0%
Q4 22	$62M	6.3%
Q1 23	$56M	6.3%
Q2 23	$61M	6.4%
Q3 23	$56M	5.8%
Q4 23	$53M	5.2%
Q1 24	$61M	6.8%
Q2 24	$57M	5.5%
Q3 24	$60M	5.7%
Q4 24	$70M	6.5%
Q1 25	$68M	7.5%
Q2 25	$65M	6.2%
Q3 25	$88M	7.8%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 21	$155M	$398M
Q1 22	$130M	$309M
Q2 22	$139M	$366M
Q3 22	$149M	$358M
Q4 22	$173M	$383M
Q1 23	$189M	$298M
Q2 23	$209M	$341M
Q3 23	$234M	$308M
Q4 23	$217M	$396M
Q1 24	$223M	$352M
Q2 24	$221M	$339M
Q3 24	$200M	$326M
Q4 24	$241M	$369M
Q1 25	$181M	$514M
Q2 25	$190M	$358M
Q3 25	$241M	$531M

Revenue Segments

Quarter	Defitelio/Defibrotide	Epidiolex/Epidyolex	Other Products	Rylaze/Enrylaze	Sativex	Vyxeos	Xyrem	Xywav	Zepzelca	High Sodium AG Oxybate Product Royalty Revenue	Other Royalty And Contract Revenues	Ziihera
Q4 21	$43M	$194M	$1M	$65M	$5M	$35M	$289M	$183M	$65M	—	—	—
Q1 22	$49M	$158M	$943.0K	$54M	$5M	$34M	$247M	$186M	$59M	—	—	—
Q2 22	$55M	$175M	$2M	$73M	$4M	$34M	$269M	$235M	$68M	—	—	—
Q3 22	$49M	$196M	$1M	$74M	$3M	$30M	$256M	$256M	$70M	—	—	—
Q4 22	$41M	$207M	$3M	$81M	$5M	$30M	$247M	$281M	$72M	—	—	—
Q1 23	$39M	$189M	$3M	$86M	$7M	$37M	$178M	$278M	$67M	$2M	$6M	—
Q2 23	$46M	$202M	$3M	$102M	$3M	$34M	$160M	$327M	$70M	$6M	$5M	—
Q3 23	$48M	$214M	$3M	$105M	$5M	$30M	$125M	$332M	$78M	$29M	$5M	—
Q1 24	$48M	$199M	$4M	$103M	$3M	$32M	$64M	$315M	$75M	$50M	$10M	—
Q2 24	$45M	$247M	$3M	$108M	$6M	$43M	$62M	$368M	$81M	$54M	$6M	—
Q3 24	$66M	$252M	$2M	$99M	$5M	$34M	$58M	$388M	$86M	$58M	$7M	—
Q4 24	$58M	$275M	$3M	$101M	$5M	$53M	$49M	$401M	$78M	$55M	—	—
Q1 25	$41M	$218M	$5M	$94M	$5M	$30M	$37M	$345M	$63M	$49M	$9M	$2M
Q2 25	$48M	$252M	$4M	$101M	$5M	$45M	$35M	$415M	$75M	$54M	$6M	$6M
Q3 25	$52M	$303M	$2M	$100M	$5M	$38M	$36M	$431M	$79M	$53M	$9M	$8M

Revenue by Geography

Quarter	Europe	Other Countries	United States
Q4 21	$65M	$8M	$824M
Q1 22	$61M	$12M	$741M
Q2 22	$61M	$14M	$858M
Q3 22	$60M	$13M	$868M
Q4 22	$58M	$11M	$904M
Q1 23	$66M	$17M	$810M
Q2 23	$59M	$13M	$885M
Q3 23	$69M	$19M	$885M
Q1 24	$71M	$22M	$808M
Q2 24	$82M	$17M	$925M
Q3 24	$77M	$24M	$954M
Q4 24	$82M	$33M	$974M
Q1 25	$84M	$16M	$798M
Q2 25	$83M	$27M	$936M
Q3 25	$86M	$19M	$1.0B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$491M	$0	$491M
Q2 22	$711M	$60M	$771M
Q3 22	$839M	$60M	$899M
Q4 22	$881M	$0	$881M
Q1 23	$1.2B	$0	$1.2B
Q2 23	$1.3B	$80M	$1.4B
Q3 23	$1.3B	$250M	$1.6B
Q4 23	$1.5B	$120M	$1.6B
Q1 24	$1.4B	$375M	$1.8B
Q2 24	$1.4B	$625M	$2.0B
Q3 24	$2.2B	$400M	$2.6B
Q4 24	$2.4B	$580M	$3.0B
Q1 25	$1.9B	$710M	$2.6B
Q2 25	$1.2B	$480M	$1.7B
Q3 25	$1.2B	$810M	$2.0B
Q4 25	$1.4B	$1.1B	$2.4B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	62M	+0.4%	+7.6%
Q1 22	63M	+2.3%	+7.7%
Q2 22	63M	+0.8%	+6.7%
Q3 22	63M	-1.0%	+2.4%
Q4 22	63M	+0.4%	+2.5%
Q1 23	74M	+17.0%	+17.3%
Q2 23	74M	-0.3%	+15.9%
Q3 23	71M	-3.1%	+13.6%
Q4 23	70M	-2.3%	+10.5%
Q1 24	63M	-10.2%	-15.2%
Q2 24	70M	+11.3%	-5.3%
Q3 24	63M	-9.3%	-11.4%
Q4 24	62M	-2.6%	-11.7%
Q1 25	61M	-0.9%	-2.5%
Q2 25	61M	+0.4%	-12.1%
Q3 25	62M	+0.7%	-2.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$280.2K	3K
Q1 22	$254.3K	3K
Q2 22	$291.5K	3K
Q3 22	$294.0K	3K
Q4 22	$347.2K	3K
Q1 23	$318.9K	3K
Q2 23	$341.9K	3K
Q3 23	$347.2K	3K
Q4 23	$361.4K	3K
Q1 24	$322.1K	3K
Q2 24	$365.7K	3K
Q3 24	$376.8K	3K
Q4 24	$388.6K	3K
Q1 25	$320.7K	3K
Q2 25	$373.5K	3K
Q3 25	$402.2K	3K

Revenue / Employee